(Q37853195)

24 August 2017

1 reference

title

Current and emerging medical therapies in the treatment of glaucoma (English)

1 reference

24 August 2017

Alessandro Bagnis

1

1 reference

24 August 2017

Marina Papadia

series ordinal

2

1 reference

24 August 2017

Riccardo Scotto

series ordinal

3

1 reference

24 August 2017

Carlo E Traverso

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

7 April 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

16

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

293-307

1 reference

Number of people with glaucoma worldwide

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Failure of medical therapy despite normal intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Persistency with latanoprost or timolol in primary open-angle glaucoma suspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Patient persistency with topical ocular hypotensive therapy in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

A comprehensive perspective on patient adherence to topical glaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Preservatives in eyedrops: the good, the bad and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Molecular and cell-based approaches for neuroprotection in glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Pharmacological neuroprotection for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Pharmacodynamics of citicoline relevant to the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Effects of latanoprost, timolol and GLC756, a novel dopamine D(2) agonist and D(1) antagonist on LTC(4) release after rat mast cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

The role of protein kinase C in modulation of aqueous humor outflow facility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Role of lysophospholipid growth factors in the modulation of aqueous humor outflow facility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

The regulation of trabecular meshwork and ciliary muscle contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Rho/Rho-kinase mediated signaling in physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Modulation of extracellular matrix turnover in the trabecular meshwork

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Mechanism of action of cytochalasin: evidence that it binds to actin filament ends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

The role of the actomyosin system in regulating trabecular fluid outflow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

What increases outflow resistance in primary open-angle glaucoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

A novel perspective on natural therapeutic approaches in glaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

Effect of protein kinase inhibitor H-7 on the contractility, integrity, and membrane anchorage of the microfilament system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.563733

10.1517/14728214.2011.563733

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference